Annexin Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase IIa clinical trial with the drug candidate ANXV for the treatment of diabetic retinopathy (DR). As part of the preparations for a future phase IIb trial, patients with newly diagnosed retinal vein occlusion (RVO) will also be included. The aim of the RVO part of the study is to evaluate a shorter treatment cycle than previously requested by potential licensees.
Read the article at biostock.se:
https://biostock.se/en/2025/08/annexin-far-gront-ljus-for-fas-iia-studie-inom-diabetesretinopati/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases